Background {#Sec1}
==========

Triple negative breast cancer (TNBC) is an operational term used to define tumors that lack expression of estrogen receptor (ER), progesterone receptor (PR) and lack amplification or overexpression of human epidermal growth factor receptor 2 (HER2) \[[@CR1], [@CR2]\]. Approximately 20% of breast cancers are TNBC \[[@CR3]\]. A small proportion of TNBCs, including adenoid cystic, secretory, adenosquamous and carcinoma, have low aggressive potential and follow an indolent course. However, the majority of TNBCs, most of which are invasive ductal carcinomas, are associated with high rates of early distant recurrence and short survival times compared to other breast cancer subtypes \[[@CR1], [@CR2], [@CR4]--[@CR9]\]. Almost all women with metastatic TNBC will die of their disease within 5 years of diagnosis \[[@CR1], [@CR3], [@CR10], [@CR11]\]; however, those who remain disease-free 8 years after initial diagnosis rarely die of breast cancer \[[@CR1], [@CR2], [@CR4]\], unlike other breast cancer subtypes.

A subgroup of TNBCs are inherently chemosensitive and achieve a pathological complete response (pCR) following combination anthracycline/taxane-based neo-adjuvant chemotherapy (NACT) \[[@CR2], [@CR12]--[@CR16]\]. These patients have a higher rate of survival compared to those with residual disease \[[@CR2], [@CR17], [@CR18]\]. The basis for this variation in response to chemotherapy and survival remains unclear. TNBCs show considerable molecular heterogeneity, and no predictive markers have been identified to date \[[@CR16], [@CR17], [@CR19]--[@CR21]\]. Consequently, efforts have focused on modifying the standard chemotherapeutic regimen using new therapeutic agents to improve outcome.

The observation that many TNBCs exhibit dysfunction of DNA damage repair pathways \[[@CR22], [@CR23]\] has led to the inclusion of platinum salts in the treatment regimen with improved rates of pCR reported both in *BRCA* mutation carriers and in sporadic tumors in several phase II trials \[[@CR12], [@CR13], [@CR24]--[@CR29]\]. These data are encouraging; however, platinum salts are not yet part of the standard treatment for TNBC and a definite survival benefit remains to be demonstrated \[[@CR30], [@CR31]\]. Despite this, carboplatin was added to the NACT regimen for TNBC in our institution in 2013 based on phase II trial data. The aim in this study was to examine the effect of carboplatin on outcome for patients with TNBC and to identify biomarkers predictive of response to treatment and outcome. Outcome data from a retrospective series of 333 patients diagnosed with TNBC, including patients treated with carboplatin added to anthracycline--taxane NACT, are presented. This cohort represents one of the largest clinical cohorts of TNBC in the literature, reported outside of the clinical trial setting.

Materials and methods {#Sec2}
=====================

Patient series {#Sec3}
--------------

The series comprised 333 consecutive patients who were diagnosed with TNBC at Galway University Hospital between January 1, 2000, and December 31, 2015. Cases were ER and PR negative by immunohistochemistry (IHC) \[[@CR32]\] and HER2 negative by IHC and/or fluorescent in situ hybridization (FISH). Twenty-seven cases with low ER expression (Allred score 3) \[[@CR32]\] were included. Tumor type and grade were re-evaluated \[[@CR33], [@CR34]\] on full-face sections of the resections or of the pre-treatment biopsy in cases where a pCR was achieved \[GC, AS\]. An adverse event was defined as a local ipsilateral recurrence; a contralateral breast cancer; a distant event \[[@CR35]\], and each was recorded as TNBC or non-TNBC. A non-breast cancer in any organ outside the breast, excluding non-melanoma skin cancer, was recorded. Deaths from breast cancer were recorded, and non-cancer-related deaths were excluded.

Adjuvant chemotherapy was the standard-of-care for TNBC prior to 2010. This changed to NACT with an anthracycline--taxane combination after 2010 with carboplatin incorporated into the NACT regime from 2013. Four patients who had very low volume oligometastatic disease in distant sites shortly after diagnosis were treated with NACT and were included with this group for analysis based on the intention-to-treat. Sixty-eight patients did not receive chemotherapy for different reasons including metastatic disease diagnosed at (*n* = 13) or shortly after diagnosis (*n* = 2); patient declined or was unfit for treatment (*n* = 27) or for reasons that were not specified (*n* = 26). Patients who had metastasis at diagnosis were excluded from analyses of DFS and MFS.

Tumors were staged according to guidelines \[[@CR36]\]. In accordance with recommendations for standardized reporting of pCR \[[@CR15], [@CR37]\], a pCR was defined as no residual invasive disease in the breast, with or without residual in situ disease, and no residual disease in the axillary lymph nodes (ypT0/isypN0) \[[@CR36]\] and is referred to as pCR breast/axilla. For the purposes of statistical analysis, pCR breast (ypT0/is) also was also examined as an endpoint.

Immunohistochemistry {#Sec4}
--------------------

TNBC status was confirmed by IHC using a tissue microarray (TMA) containing 2 mm tumor cores in cases that had sufficient tumor using ER (SP1 Rabbit Monoclonal antibody; Thermo-Scientific; Dilution 1:00); PR (16/SAN27 Mouse Monoclonal antibody; Lecia; Dilution 1:200); and HER2 (4B5 Rabbit Monoclonal antibody; Roche; pre-filled dilution) with HER2 FISH as required and reported according to current guidelines \[[@CR38], [@CR39]\]. Cases were classified as basal if there was any positivity for cytokeratin (CK) 5/6 (D5/16, B4 Mouse Monoclonal antibody; Dako; Dilution 1:100) or epidermal growth factor receptor (EGFR) (EGFR.25; Leica; Dilution 1:100) \[[@CR4]\] on full-face sections at diagnosis for some cases; on core biopsies for cases that had a pCR post-NACT; and on TMA sections for other cases.

Statistical analysis {#Sec5}
--------------------

The Kruskal Wallis test with Dunn's post-estimation and Fisher's exact test were used to examine the differences in age and clinico-pathological characteristics between treatment groups, respectively. Differences in follow-up and survival times were analyzed using Oneway Anova with Bonferroni post-estimation. Associations between clinico-pathological characteristics and survival were assessed using log-rank tests with two proportion tests to estimate the effect (difference in proportions) of significant variables. Pearson *χ*^2^ testing was used to assess the interaction between variables. Both univariate and multivariate Cox regression analyses were used to calculate hazard ratios (HR) and 95% confidence intervals (95% CI), adjusting for variables. Logistic regression analysis was used to calculate odds ratio (OR) and 95% CI to adjust for prognostic variables. Test for trend of survivor testing assessed the impact of increasing prognostic variables on outcomes. Kaplan--Meier estimates were plotted for disease-free survival (DFS), metastases-free survival (MFS) and breast cancer-specific survival (BCSS). *p values* reported were two-tailed, and *p* \< 0.05 was considered statistically significant. Statistical analysis was performed using Stata/IC (v14.0) and SPSS (v24).

Results {#Sec6}
=======

Patient and tumor characteristics {#Sec7}
---------------------------------

Patient demographics and tumor characteristic are shown in Table [1](#Tab1){ref-type="table"}. Overall, 51% of patients received adjuvant chemotherapy (*n* = 168) and 29% (*n* = 97) patients received NACT. Patients who received NACT were younger than those in the other treatment groups (*p* \< 0.001). Tumor type differed between the groups (*p* = 0.004). Lobular carcinomas accounted for 5% of TNBCs, most of which were pleomorphic ILC, and were more common in those who did not receive chemotherapy. More of those who received NACT had grade 2 tumors compared to patients treated with adjuvant therapy (*p* \< 0.001). The follow-up time was shorter for those who received NACT compared to those who received adjuvant therapy (median 30 months; range 5--126 and median 64 months, range 2--186, respectively), which paralleled the shift from adjuvant chemotherapy to NACT since 2010.

Table 1Patient and tumor characteristicsParameterAll patientsNACTAdjuvant CTNo CT*p* Value*p* Value*n* (%)*n* (%)*n* (%)*n* (%)None versus NACT versus AdjuvantNACT versus Adjuvant CTNumber of patients33397 (29%)168 (51%)68 (20%)Age at diagnosis (years)Median55485575\< 0.001\< 0.001Range24--9224--7330--7930--92MenopausalPre119 (36%)57 (59%)58 (35%)4 (6%)\< 0.001\< 0.001StatusPost200 (60%)33 (34%)105 (62%)62 (91%)Unknown14 (4%)7 (7%)5 (3%)2 (3%)BRCA mutationNone240 (72%)69 (71%)129 (77%)42 (62%)0.0860.807BRCA1 mutation12 (4%)4 (4%)8 (5%)0BRCA2 mutation7 (2%)2 (2%)5 (3%)0Unknown74 (22%)22 (23%)26 (15%)26 (38%)Family history of breast cancerNo123 (55%)40 (56%)66 (54%)17 (55%)0.9560.763Yes101 (45%)31 (44%)56 (46%)14 (45%)Tumor typeDuctal271 (81%)87 (90%)138 (82%)46 (68%)0.0040.595Lobular16 (5%)1 (1%)7 (4%)8 (15%)Metaplastic15 (5%)4 (4%)6 (4%)5 (7%)Medullary14 (4%)4 (4%)8 (5%)2 (3%)Apocrine9 (3%)1 (1%)2 (1%)6 (9%)Other^a^4 (1%)03 (2%)1 (1%)Unknown4 (1%)04 (2%)0Tumor grade11 (0.5%)01 (1%)0\< 0.001\< 0.001263 (19%)27 (28%)15 (9%)21 (31%)3265 (79.5%)70 (72%)148 (88%)47 (69%)Unknown4 (1%)04 (2%)0Basal status^b^Positive254 (76%)79 (81%)131 (78%)44 (65%)0.2250.227Negative57 (17%)12 (12%)31 (18%)14 (20%)Unclassified22 (7%)6 (6%)6 (4%)10 (15%)pT stage178 (33%)NA57 (34%)21 (34%)0.088NA2121 (51%)92 (55%)29 (48%)311 (5%)8 (4.5%)3 (5%)414 (6%)6 (4%)8 (13%)Unknown12 (5%)5 (3%)7pN stage0140 (59%)NA104 (62%)36 (53%)0.619NA143 (18%)33 (20%)10 (15%)219 (8%)12 (7%)7 (10%)314 (6%)8 (5%)4 (6%)Unknown22 (9%)11 (6%)11 (16%)ypT stage035 (36%)35 (36%)NANANANAIn situ8 (8%)8 (8%)127 (28%)27 (28%)212 (13%)12 (13%)35 (5%)5 (5%)410 (10%)10 (10%)ypN stage064 (66%)64 (66%)NANANANA111 (11%)11 (11%)213 (14%)13 (14%)38 (8%)8 (8%)Unknown1 (1%)1(1%)M stage0316 (95%)93 (96%)168 (100%)55 (81%)\< 0.0010.008117 (5%)4 (4%)013 (19%)ChemotherapyAnthra., Taxane124 (47%)64 (66%)60 (36%)NANANAAgents^c^Taxane64 (24%)064 (38%)Anthra., Taxane, carboplatin31 (12%)31 (32%)0Anthra30 (11%)030 (18%)Other6 (2%)06 (3%)Unknown regimen10 (4%)2 (2%)8 (5%)OutcomeAll new adverse events^d,e^88 (28%)21 (23%)46 (27%)21 (38%)0.1210.395Ipsilateral recurrence (TNBC)13 (4%)1 (1%)8 (5%)4 (7%)Ipsilateral recurrence (non-TNBC)2 (0.6%)01 (0.6%)1 (2%)Contralateral IBC (TNBC)3 (1%)03 (2%)0Contralateral IBC (non-TNBC)1 (0.3%)1 (1%)00Distant event59 (19%)19 (20%)26 (15%)14 (25%)Other cancer (non-breast)10 (3%)08 (5%)2 (4%)Death from disease^f^68 (22%)18 (19%)25 (16%)25 (39%)Follow-up time (months)Median43306424\< 0.001\< 0.001Range0--1995--1262--1860--199*Anthra* Anthracycline, *CT* chemotherapy, *n* number of patients, *IBC* invasive breast cancer, *NACT* neoadjuvant chemotherapy, *NA* not applicable, *TNBC* triple negative breast cancer^a^Other tumor types include micropapillary (*n* = 1); mixed ductal-lobular (*n* = 1), mixed ductal-micropapillary (*n* = 1) and papillary carcinoma (*n* = 1); ILC comprised pleomorphic ILC (*n* = 13) and classic ILC (*n* = 3)^b^Basal status: any positivity for either cytokeratin 5/6 or EGFR by immunohistochemistry^c^Chemotherapeutic agents listed for patients known to have received either adjuvant chemotherapy or NACT^d^All new adverse events were classified according to Maastricht Delphi consensus criteria \[[@CR35]\]. All distant events of breast cancer were TNBC. There were no adverse events that were either regional axillary or in situ disease. Non-melanoma skin cancer was excluded from other cancer that was non-breast. Metastatic disease at diagnosis was not regarded as a new event^e^Number of patients evaluable for new adverse events excluding death from disease (DFS, MFS) = 316: NACT (*n* = 93), adjuvant chemotherapy (*n* = 168), no CT (*n* = 55)^f^Number of patients evaluable for death (BCSS) = 321: NACT (*n* = 96), adjuvant therapy (*n* = 161), no chemotherapy (*n* = 64)

Treatment {#Sec8}
---------

NACT consisted of an anthracycline--taxane combination with platinum included for 31 patients. Paclitaxel was given weekly for 12 weeks with carboplatin administered at an AUC = 5 mg\*min/mL every 3 weeks, followed by dose dense doxorubicin plus cyclophosphamide. NACT was reasonably well tolerated, albeit with more toxicities recorded among those who received carboplatin: 19% (*n* = 6) versus 13% (*n* = 8) had a treatment delay; 19% (*n* = 6) versus 5% (*n* = 3) failed to complete their recommended course of treatment; and 7% (*n* = 2) versus 0% had a dose reduction in the platinum and non-platinum treated group, respectively. Despite failing to complete their recommended NACT, four of six patients treated with carboplatin achieved a pCR, whereas none of the three patients treated with non-platinum NACT who failed to complete their NACT achieved a pCR. In the adjuvant setting, most patients received a taxane; an anthracycline--taxane; or an anthracycline combination (Table [1](#Tab1){ref-type="table"}). All adjuvant chemotherapy was well tolerated. Treatment delays were seen in 22%, 20% and 3% among anthracycline, anthracycline--taxane and taxane combinations, respectively, and dose reductions were very infrequent (\< 5%). Adjuvant endocrine therapy was given in the case of cancers with low (\< 10%) ER or PR expression, or for an ER positive recurrence.

Outcomes {#Sec9}
--------

The median DFS, MFS and BCSS for all patients was 39.5, 40.5 and 44 months (range 0--199 months), respectively. The DFS, MFS and BCSS in the different treatment groups was compared (Fig. [1](#Fig1){ref-type="fig"}). There were statistically significant differences between the three treatment groups but there was no significant difference in DFS (log-rank test, *p* = 0.352) or MFS (log-rank test, *p* = 0.094) between patients receiving NACT versus adjuvant therapy. However, a marginally significant improvement in BCSS was seen in patients receiving adjuvant therapy compared to NACT (log-rank test, *p* = 0.049).

Fig. 1Disease-free, metastases-free and breast cancer-specific survival for patients according to schedule of chemotherapy. Kaplan--Meier cumulative survival curves for **a** disease-free survival and **b** metastases-free survival for patients who received adjuvant chemotherapy (CT) (*n* = 168), neoadjuvant CT (*n* = 93) or no CT (*n* = 55) (log-rank test DFS, *p* value = 0.024) and (log-rank test MFS, *p* value = 0.045). **c** Kaplan--Meier cumulative survival curves for breast cancer-specific survival for patients for patients who received adjuvant therapy (*n* = 161), neoadjuvant CT (*n* = 96) or no CT (*n* = 64) (log-rank test, *p* value \< 0.001)

The number of new adverse events in the different treatment groups was similar (*p* = 0.121) (Table [1](#Tab1){ref-type="table"}), and most of these (67%, *n* = 59) were distant recurrences of TNBC. Distant metastases were more common than local recurrences as a first event in the NACT group compared to the adjuvant therapy group (*p* = 0.029). Irrespective of whether local recurrence or distant metastatic disease developed first, there was no difference in the number of patients who ultimately developed metastatic disease in the NACT or adjuvant therapy groups (*p* = 0.527). A new non-TNBC breast cancer was uncommon (3%, *n* = 3); as was a cancer outside the breast (11%, *n* = 10), most of which occurred in those who received adjuvant therapy, possibly due to their longer follow-up time. Overall, 22% (*n* = 68) of patients died from TNBC; this included 64 patients who had non-metastatic disease at diagnosis. The time from recurrence to death was short for all patients (median 8 months; 0--33). There were no treatment-related deaths.

Response to NACT {#Sec10}
----------------

A pCR breast (ypT0/is) was observed in 43 patients (44%), including eight who had residual in situ disease only; 37 patients (38%) had a pCR breast/axilla (ypT0/isN0). A pCR breast was significantly more common in patients who received carboplatin (*n* = 18, 58%) compared to those who did not (*n* = 23, 36%) (Pearson *χ*^2^ = 4.81; *p* = 0.041). Likewise, a pCR breast/axilla was more frequent with carboplatin therapy (*n* = 17, 55%) than without it (*n* = 18, 28%) (Pearson *χ*^2^: 6.41, *p* = 0.011). Univariate logistic regression analysis (Table [2](#Tab2){ref-type="table"}) revealed that the likelihood of both a pCR breast and pCR breast/axilla was highest after carboplatin (OR~non-pCR~ = 0.38; 95% CI 0.16--0.91, *p* = 0.030; OR 0.32; 95% CI 0.13--0.79; *p* = 0.013, respectively); and in grade 3 tumors (OR 0.15; 95% CI 0.05--0.47; *p* = 0.001; OR 0.08; 95% CI 0.02--0.36; *p* = 0.001, respectively). A family history of breast cancer increased the likelihood of a pCR breast (OR 0.34; 95% CI 0.13--0.90; *p* = 0.030) but not of a pCR breast/axilla (OR 0.51; 95% CI 0.19--1.31; *p* = 0.162); 61% of those with a family history of breast cancer achieved a pCR breast compared to 35% of those without a family history (Pearson *χ*^2^ = 4.85; *p* = 0.028). *BRCA1*/*2* mutation status did not increase the likelihood of a pCR, but four of the six *BRCA1*/*2* mutation carriers had a pCR breast, and the remaining two patients had a near total response (ypT1mi or ypT1b). None of the other parameters were associated with pCR on univariate analysis.

Table 2Univariate and multivariable analyses of predictors of pCR breast and pCR breast/axilla*N*OR^a^95% CI*p* ValueUnivariate analysis pCR breast  Age at diagnosis971.020.98--1.050.434  Menopausal status901.060.45--2.520.895  Family history of breast cancer710.340.13--0.900.030  Tumor type970.910.65--1.260.557  Tumor grade970.150.05--0.470.001  Basal status^b^910.630.18--2.260.477  Platinum-based NACT950.380.16--0.910.030 pCR breast/axilla  Age at diagnosis971.010.98--1.050.454  Menopausal status901.10.45--2.670.833  Family history of breast cancer710.510.19--1.320.162  Tumor grade970.080.02--0.360.001  Tumor type971.040.73--1.480.815  Basal status^b^910.490.12--1.950.311  Platinum-based NACT950.320.13--0.790.013Multivariable analysis pCR breast95  Age at diagnosis1.000.96--1.050.892  Tumor grade0.100.03--0.370.001  Platinum-based NACT0.260.09--0.740.011 pCR breast/axilla95  Age at diagnosis1.010.97--1.050.704  Tumor grade0.050.01--0.27\< 0.001  Platinum-based NACT0.170.06--0.540.002*n* Number of patients, *OR* odds ratio, *CI* confidence interval, *NACT* neoadjuvant chemotherapy, *pCR* pathological complete response^a^OR for a non-pCR by Logistic regression analysis^b^Basal status: any positivity for either cytokeratin 5/6 or EGFR by immunohistochemistry

By multivariable analysis (Table [2](#Tab2){ref-type="table"}), carboplatin therapy (OR 0.26; 95% CI 0.09--0.74; *p* = 0.011) and grade 3 histology (OR 0.10; 95% CI 0.03--0.37; *p* = 0.001) remained independently associated with a pCR breast and with a pCR breast/axilla (OR 0.17; 95% CI 0.06--0.54; *p* = 0.002, and OR 0.05; 95% CI 0.01--0.27; *p* \< 0.001 for carboplatin and grade, respectively).

DFS, MFS and BCSS {#Sec11}
-----------------

### Patients treated with NACT {#Sec12}

By univariate analyses (Supplementary Tables 1 and 2), both pCR endpoints increased the likelihood of an improved DFS, MFS and BCSS. The magnitude of the effect of pCR on outcome was greatest for pCR breast/axilla for DFS (HR = 6.66; 95% CI 1.54--28.58; *p* = 0.011); for MFS (HR = 5.90; 95% CI 1.36--25.56; *p* = 0.018); and for BCSS (HR = 10.30; 95% CI 1.37--77.38; *p* = 0.023) (Fig. [2](#Fig2){ref-type="fig"}).

Fig. 2Disease-free, metastases-free and breast cancer-specific survival according to pathological response to NACT. Kaplan--Meier cumulative survival curves show the association between pathological complete response (pCR) breast/axilla and **a** disease-free survival (*n* = 93) log-rank test, *p* value = 0.003; **b** metastases-free (*n* = 93) log-rank test, *p* value = 0.007; and **c** breast cancer-specific survival (*n* = 96) log-rank test, *p* value = 0.005. A pCR breast/axilla is defined as ypT0/isN0

There was a significant trend of association between increasing ypT category and adverse DFS (*χ*^2^ test for trend, 13.56; *p* = 0.002), MFS (*χ*^2^ test for trend, 12.90; *p* = 0.0003) and BCSS (*χ*^2^ test for trend, 11.14; *p* = 0.0008). However, there was no significant difference in outcome for patients with ypT1 versus ypT0/ypT0/is disease. A significant trend of association was also observed between an increasing number of positive nodes and adverse DFS (*χ*^2^ test for trend, 18.32; *p* \< 0.0001), MFS (*χ*^2^ test for trend, 17.20; *p* \< 0.001) and BCSS (*χ*^2^ test for trend, 33.56; *p* \< 0.001). The outcome was worst for those with ypN3 disease (Supplementary Tables 1 and 2).

On multivariable analyses (Table [3](#Tab3){ref-type="table"}), a pCR breast/axilla was the only independent predictor of DFS (HR = 6.23; 95% CI 1.36--28.50; *p* = 0.018), MFS (HR = 5.08; 95% CI 1.09--23.65; *p* = 0.038) and BCSS (HR = 8.52; 95% CI 1.09--66.64; *p* = 0.041), when adjusted for age at diagnosis, tumor grade, tumor type, basal status and the administration of carboplatin. In a separate multivariable model using the same co-variables, pCR breast also remained the only independent predictor of DFS, MFS and BCSS (Supplementary Table 3).

Table 3Multivariable analysis of DFS, MFS and BCSS for patients treated with NACT*n*HR^a^95% CI*p* ValueDisease-free survival85 Age at diagnosis0.990.95--1.040.776 Tumor grade1.050.39--2.810.926 Tumor type0.640.27--1.490.298 Basal status^b^1.610.36--7.200.530 Platinum-based therapy0.680.18--2.560.566 pCR breast/axilla^c^6.231.36--28.500.018Metastasis-free survival85 Age at diagnosis0.990.95--1.040.841 Tumor grade0.850.31--2.370.759 Tumor type0.670.30--1.520.343 Basal status^b^1.470.32--6.630.619 Platinum-based therapy0.690.18--2.650.590 pCR breast/axilla^c^5.081.09--23.650.038Breast cancer-specific survival88 Age at diagnosis1.010.96--1.060.714 Tumor grade1.140.40--3.260.813 Tumor type0.770.40--1.490.441 Basal status^b^1.320.29--6.070.719 Platinum-based therapy0.3100.04--2.500.272 pCR breast/axilla^c^8.521.09--66.640.041*n* Number of patients, *HR* hazard ratio, *CI* confidence interval^a^Cox regression survival analysis^b^Basal status: any positivity for either cytokeratin 5/6 or EGFR by immunohistochemistry^c^HR for non-pCR using pCR as the baseline value

The association between carboplatin therapy and outcome limited to 24-month follow-up time was examined (Fig. [3](#Fig3){ref-type="fig"}) because the median follow-up time for patients who received carboplatin was short (18 months; range 8--34). DFS was improved with platinum therapy but the association did not reach statistical significance on univariate (HR~non-pCR~ = 0.34; 95% CI 0.75--1.50; *p* = 0.153) or multivariable analysis (Supplementary Table 4).

Fig. 3Disease-free survival for patients who received NACT according to the administration of platinum agents. Kaplan--Meier curves show the disease-free survival for patients stratified according to the administration of platinum-based NACT. The analysis was confined to 24-month follow-up period because the follow-up time for patients who received a platinum agent was short. A new event was observed in two of 31 patients who received a platinum and in 12 of 60 patients who received standard anthracycline--taxane-based NACT (log-rank test, *p* value = 0.262)

### Patients who did not receive NACT {#Sec13}

Univariate analysis (Supplementary Tables 1 and 2) revealed that increasing tumor size (pT) and nodal status were a significant risk factor for adverse DFS (*χ*^2^ test trend 8.83, *p* = 0.003; and 29.06, *p* \< 0.001, respectively); MFS (*χ*^2^ test trend 24.92, *p* \< 0.001) and BCSS (*χ*^2^ test trend 32.40, *p* \< 0.001 and 29.46, *p* \< 0.001, respectively). A strong positive correlation between tumor size and nodal status (Pearson *χ*^2^ = 73.01, *p* \< 0.001) was noted. However, there was no difference in outcome for pT2 and pT1 tumors or between pN1 and node negative disease.

Multivariable analysis (Table [4](#Tab4){ref-type="table"}) revealed that only nodal stage at diagnosis was an independent predictor of DFS (HR = 1.75; 95% CI 1.30--2.34; *p* \< 0.001), and both nodal status (HR = 1.58; 95% CI 1.13--2.23; *p* = 0.008) and tumor size (HR = 1.68; 95% CI 1.10--2.58; *p* = 0.018) were independent predictors of MFS. When those with M1 at diagnosis were excluded, pT was the only independent predictor of BCSS (HR = 2.08; 95% CI 1.39--3.11; *p* \< 0.001). In a separate analysis including those with M1 disease at diagnosis, metastasis and tumor size were independent predictors of BCSS.

Table 4Multivariable analysis of DFS, MFS and BCSS in patients treated with adjuvant or no chemotherapy*n*HR^a^95% CI*p* ValueDisease-free survival206 Age at diagnosis1.020.99--1.040.128 Tumor grade0.780.40--1.510.455 pT1.070.73--1.590.723 pN1.751.30--2.34\< 0.001Metastases-free survival206 Age at diagnosis1.010.99--1.040.275 Tumor grade1.180.47--3.040.340 pT1.701.10--2.620.017 pN1.571.11--2.210.009Breast cancer-specific survival203 Age at diagnosis1.010.99--1.040.238 Tumor grade1.460.57--3.760.427 pT2.051.37--3.100.001 pN1.300.91--1.840.154 M1 at diagnosis7.662.72--20.08\< 0.001*n* number of patients, *HR* hazard ratio, *CI* confidence interval, *nc* not calculable, *M1* metastatic disease^a^HR for non-pCR by Cox regression survival analysis using pCR as the baseline value

There was no association between tumor type and outcome (Table [3](#Tab3){ref-type="table"}, Supplementary Tables 1, 2). Metaplastic carcinomas were uncommon (*n* = 15); however, we observed that only five of the 15 patients died from disease after a median time to recurrence of 26 months (range 0--44 months) and median time to death of 32 months (range 2--58 months). There was no difference in survival for patients with metaplastic carcinoma between the three treatment groups.

Discussion {#Sec14}
==========

We show in a retrospective series that patients with TNBC who received carboplatin with anthracycline--taxane-based NACT have significantly higher rate of pCR compared to those who received anthracycline/taxane alone. A pCR breast and a pCR breast/axilla, achieved in 58% and 55% of those treated with carboplatin, respectively, were the only independent predictors of survival, although follow-up time was short. In patients who did not received NACT, only traditional parameters of nodal status and tumor size had prognostic significance.

Several studies have shown the favorable association between pCR and outcome \[[@CR40]--[@CR43]\]; patients with TNBC who attain a pCR have an outcome that is comparable to that for patients with non-TNBC who attain a pCR \[[@CR2], [@CR14], [@CR15], [@CR44]\]. It is generally accepted that a pCR breast/axilla is a stronger predictor of outcome than a pCR breast, which was shown in our series where a pCR breast/axilla was a stronger predictor of BCSS than a pCR breast for analyses of BCSS. However, this difference in benefit was not observed for DFS or MFS on multivariate analysis, where both pCR endpoints improved DFS and MFS comparably. The benefit of a pCR in terms of survival shown in our data has been reported by others \[[@CR13], [@CR15], [@CR45], [@CR46]\]. However, the prognostic value of pCR has not yet been validated at trial level, as reported in the pooled analysis of almost 12,000 patients \[[@CR15]\]; and it is likely that other variables affect the relationship between pCR and survival that should be examined in future trials examining the prognostic value of pCR \[[@CR46], [@CR47]\].

The rate of pCR in our series is comparable to that reported in two prospective randomized phase II clinical trials evaluating carboplatin with anthracycline--taxane NACT in stage II-III TNBC. In the GeparSixto trial, carboplatin and bevacizumab resulted in an increase from 37 to 53%, in the rate of pCR in 158 patients \[[@CR13]\]. The Alliance study \[[@CR12]\] reported a pCR of 54% in those treated with carboplatin with an alkylating agent. Similarly, in a smaller series, Ando et al. \[[@CR26]\] reported a pCR in 61% for those treated with carboplatin with anthracycline--taxane. Only the earlier GEICAM randomized trial failed to show any improvement in pCR rate with carboplatin \[[@CR48]\]. The phase II adaptively randomized I-SPY 2 study \[[@CR25]\] which assessed the addition of a poly-ADP-ribose-polymerase (PARP) inhibitor, veliparib, plus carboplatin to anthracycline--taxane NACT also reported a pCR in 51% of those who received veliparib and carboplatin.

The data from these studies are promising; however, the optimal way of incorporating platinum agents in the NACT regimen is not yet established \[[@CR49]\]. In the GeparSixto and Ca.Pa.Be studies, different anthracycline--taxane combinations were used and bevacizumab was given \[[@CR13], [@CR28]\]. The dose of carboplatin also differed between studies: GEICAM \[[@CR48]\], CALGB 40603 \[[@CR12]\] and I-SPY2 \[[@CR25]\] used carboplatin every 3 weeks at an AUC = 6; Ando et al. \[[@CR26]\] used carboplatin every 3 weeks at an AUC = 5; Ca.Pa.Be \[[@CR28]\] used weekly carboplatin at AUC = 2 and the GeparSixto (13) used weekly carboplatin at an AUC = 1.5. In our institution, paclitaxel is given weekly for 12 weeks with carboplatin administered at an AUC = 5 every 3 weeks, followed by dose dense doxorubicin plus cyclophosphamide. Platinum agents are reportedly associated with increased toxicity relative to the standard chemotherapeutic regimen \[[@CR12], [@CR13]\]. Some suggest that carboplatin plus paclitaxel may have less hematological toxicities than carboplatin plus docetaxel \[[@CR50]--[@CR52]\] but others report good tolerance of carboplatin plus docetaxel in an anthracycline-free regimen \[[@CR53]\]. In our cohort, toxicities and treatment delays were increased in those who received carboplatin, nonetheless most of those who received carboplatin but did not complete their still achieved a pCR.

Tumor grade was the only other independent predictor of pCR in this study and is in keeping with reported increased chemo-sensitivity for grade 3 compared to low-grade TNBCs \[[@CR16]\]. This emphasizes the importance of accurate tumor grading in pre-NACT tumor material. Although most TNBCs are grade 3, we and others have recorded that between 16 and 21% of TNBCs are not high grade in series that exclude the low-grade indolent subtypes of TNBC \[[@CR54], [@CR55], present series\]. Tumour histological type was not a prognostic factor in our series. The proportion of ILC in our series (5%) was greater than the 1% reported by others in 20,000 to 90,000 TNBCs \[[@CR54]--[@CR56]\]. However, it was comparable to the 7.7% of ILC recorded in a series 841 TNBCs \[[@CR57]\], which suggests that the discrepancy may relate to the size of series. Metaplastic carcinomas were also uncommon, but we noted that two-thirds of patients with this subtype were disease-free after a median follow-up of 40 months (range 2--154 months). None of the other parameters examined in this study had prognostic or predictive significance.

Basal status by IHC was not informative, which contrasts with reports of adverse outcome for basal TNBCs \[[@CR4]\] and with data showing higher rates of pCR for 'Basal-like 1' TNBCs defined by the TNBC type-4 \[[@CR16], [@CR58]\]. There is, as yet, no consensus on either the definition or on the clinical significance of the basal phenotype. Tumors identified as basal using different platforms overlap \[[@CR4], [@CR6], [@CR16], [@CR17], [@CR19], [@CR20], [@CR59]\], but different platforms do not characterize the same tumors as basal. The majority of TNBCs in our series arose in the sporadic setting; however, a pCR breast was significantly associated with a family history of breast cancer, which may point to enhanced chemo-sensitivity or possibly 'BRCA-ness' in those with a family history \[[@CR22], [@CR23]\].

The overall outcome and pattern of recurrence for all patients in our series is in line with that reported by others \[[@CR1], [@CR2], [@CR4]--[@CR8]\]. Early distant metastases were more common that local recurrences as a first event, and the median survival time from first was only 8 months. In the non-neoadjuvant setting, tumor size and nodal status were the only predictors of outcome with a significant positive trend of association between these variables and outcome observed. However, there was no survival difference between patients with pT2 versus pT1 disease or between those with pN1 versus pN0 disease. This is at variance with other reports \[[@CR5]\], in which outcome was related to nodal positivity versus node negative disease and not the number of positive nodes. This inconsistency may be explained by the small number of cases with N1 disease (*n* = 48) in our series. A nonlinear correlation between both nodal status and tumor size with outcome in TNBC has been observed by others \[[@CR1], [@CR60], [@CR61]\] which suggests that tumor size and extent may be less valid for TNBC with its more aggressive biological behavior than for breast cancer as a whole.

There were limitations with this study. First, the median follow-up time for the NACT group was 30 months and only 18 months for those received carboplatin, reflecting the change in chemotherapy practice over time. Notwithstanding, the natural history of early recurrences peaking between within 3 years of diagnosis for TNBCs \[[@CR1], [@CR2], [@CR4]--[@CR8]\] mitigates to some degree the effect of short follow-up time on DFS. Also, the size of our series was not large enough to explore prognostic differences between subsets of TNBC. However, this study represents one of the largest clinical TNBC cohorts reported; we identified very few studies, performed outside of clinical trials, with larger cohorts of TNBC patients \[[@CR5], [@CR62]--[@CR64]\]. These focused on surgical procedures \[[@CR62], [@CR63]\] or loco-regional recurrences as primary outcomes \[[@CR64]--[@CR66]\]. Even when clinical trials are included, this cohort represents a large, significant patient sample as only the BEATRICE (*n* = 2591) \[[@CR65]\], GeparQuinto (*n* = 663) \[[@CR66]\], NSABP-B40 (*n* = 479) \[[@CR67]\] and CALGB 40603 (*n* = 433) \[[@CR12]\] trials had larger TNBC patient cohorts.

The ypT stage assigned by the reporting breast pathologist at the time of diagnosis was used for analyses. Other systems that measure the degree of response to chemotherapy \[[@CR68], [@CR69]\] were reported inconsistently before 2013 and were not used for analysis. The Residual Cancer Burden score may be more promising than the TNM system for post-NACT staging; it provides an index that is predictive of long-term survival with reports of good reproducibility \[[@CR37], [@CR69]--[@CR71]\]. Finally, 27 patients with low ER expression (1--9% positivity) were included. The optimal treatment for these 'ER-poor' cancers is not defined. In our institution, these are treated as ER negative disease, although some receive adjuvant endocrine therapy. Whether including these patients could skew our results is a legitimate question; however, molecular subtype analysis suggests that the majority of these cancers have the same profiles and clinical outcome as ER negative disease \[[@CR72], [@CR73]\].

In summary, our data demonstrate that carboplatin added to anthracycline--taxane NACT significantly improves the rate of pCR in TNBC and that pCR is the only independent predictor of outcome, albeit at relatively short follow-up time. Grade 3 histology was the only other independent predictor of pCR, underscoring the importance of accurate evaluation of grade in TNBCs pre-NACT. Platinum therapy is not yet standard-of-care for TNBC. While awaiting results from phase III trials examining the survival advantage for platinums (NCT02488967; NCT02445391), our results add to the data supporting the incorporation of carboplatin with anthracycline--taxane NACT \[[@CR74]\]. It remains unclear whether all or a subset of TNBCs derive benefit from platinum and identification of predictive biomarkers of response are required.
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AUC

:   Area under the curve

BCSS

:   Breast cancer-specific survival

BCT

:   Breast conserving therapy

*BRCA1*/*2*

:   Breast cancer gene 1/2

CALGB

:   Cancer and Leukemia Group B

CI

:   Confidence interval

CK

:   Cytokeratin

DFS

:   Disease-free survival

EGFR

:   Epidermal growth factor receptor

ER

:   Estrogen receptor

FISH

:   Fluorescent in situ hybridization

GUH

:   Galway University Hospital

HER2

:   Human epidermal growth factor receptor 2

H&E

:   Hematoxylin and eosin stain

HR

:   Hazard ratio

IHC

:   Immunohistochemistry

M1

:   Metastatic disease

MFS

:   Metastasis-free survival

NACT

:   Neoadjuvant chemotherapy

NSABP

:   National Surgical Adjuvant Breast and Bowel Project

NST

:   No special type

OR

:   Odds ratio

OS

:   Overall survival

PARP

:   Poly-ADP-ribose-polymerase

pCR

:   Pathological complete response

PR

:   Progesterone receptor

TMA

:   Tissue microarray

TNBC

:   Triple negative breast cancer
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